{Reference Type}: Case Reports
{Title}: Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review.
{Author}: Yu Y;Yu M;Li Y;Zhou X;Tian T;Du Y;Tu Z;Huang M;Yu Y;Yu M;Li Y;Zhou X;Tian T;Du Y;Tu Z;Huang M;
{Journal}: Front Oncol
{Volume}: 12
{Issue}: 0
{Year}: 2022
{Factor}: 5.738
{DOI}: 10.3389/fonc.2022.945620
{Abstract}: BRAF gene has been identified as an oncogenic driver and a potential target in various malignancies. BRAF fusions are one subtype of BRAF alterations with a rare frequency. Here, we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves partial response to the MAK inhibitor trametinib. We also provide a literature review on targeted therapies for BRAF fusions.